Your browser is no longer supported. Please, upgrade your browser.
Settings
SCLN SciClone Pharmaceuticals, Inc. daily Stock Chart
SCLN [NASD]
SciClone Pharmaceuticals, Inc.
Index- P/E12.45 EPS (ttm)0.75 Insider Own0.50% Shs Outstand51.46M Perf Week-1.06%
Market Cap481.15M Forward P/E8.58 EPS next Y1.09 Insider Trans-58.75% Shs Float46.63M Perf Month-6.03%
Income37.50M PEG0.88 EPS next Q0.24 Inst Own74.20% Short Float3.28% Perf Quarter-5.08%
Sales166.50M P/S2.89 EPS this Y11.40% Inst Trans0.39% Short Ratio6.44 Perf Half Y-7.88%
Book/sh4.54 P/B2.06 EPS next Y18.48% ROA15.90% Target Price14.00 Perf Year-28.24%
Cash/sh- P/C- EPS next 5Y14.10% ROE17.60% 52W Range8.55 - 15.02 Perf YTD-13.43%
Dividend- P/FCF18.16 EPS past 5Y5.10% ROI13.80% 52W High-37.77% Beta1.76
Dividend %- Quick Ratio9.60 Sales past 5Y3.80% Gross Margin86.00% 52W Low9.36% ATR0.27
Employees570 Current Ratio10.30 Sales Q/Q17.50% Oper. Margin22.90% RSI (14)42.16 Volatility2.86% 2.80%
OptionableYes Debt/Eq0.00 EPS Q/Q81.90% Profit Margin22.50% Rel Volume0.47 Prev Close9.30
ShortableYes LT Debt/Eq0.00 EarningsMay 10 AMC Payout0.00% Avg Volume237.98K Price9.35
Recom2.00 SMA20-2.88% SMA50-3.33% SMA200-6.48% Volume112,716 Change0.54%
Nov-29-16Initiated Maxim Group Buy $14
Nov-14-14Downgrade BWS Financial Buy → Hold $8.25 → $8
Nov-12-13Reiterated Aegis Capital Buy $9 → $8
Jul-16-13Upgrade Aegis Capital Hold → Buy $9
Sep-18-12Upgrade BWS Financial Hold → Buy $8.25
Aug-10-10Downgrade BWS Financial Buy → Hold $7.25 → $4.50
Apr-09-10Upgrade BWS Financial Hold → Buy $7.25
Jul-08-09Downgrade BWS Financial Buy → Hold $3.25
Jun-03-09Initiated ThinkEquity Buy $5
May-21-09Initiated Rodman & Renshaw Mkt Outperform $5
Sep-05-08Initiated Susquehanna Financial Neutral
May-16-17 01:15PM  Edited Transcript of SCLN earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 09:00PM  Edited Transcript of SCLN earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents
05:28PM  SciClone posts 1Q profit Associated Press
04:05PM  SciClone Reports First Quarter 2017 Financial Results PR Newswire
08:14AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : May 10, 2017 Capital Cube
May-04-17 06:00AM  SciClone Pharmaceuticals To Report First Quarter 2017 Financial Results On May 10, 2017 PR Newswire
Apr-26-17 04:33PM  SciClone Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCLN) : April 26, 2017 Capital Cube
Apr-25-17 08:59AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : April 25, 2017 Capital Cube
Apr-11-17 08:41AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : April 11, 2017 Capital Cube
Mar-27-17 06:00AM  SciClone To Present At Needham Healthcare Conference On April 4, 2017 PR Newswire
Mar-23-17 09:09AM  SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017 Capital Cube
09:09AM  SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017
Mar-20-17 07:25AM  How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma PR Newswire
Mar-15-17 01:04PM  SCICLONE PHARMACEUTICALS INC Financials
Mar-06-17 12:40PM  Edited Transcript of SCLN earnings conference call or presentation 6-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
07:56AM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q4 2016 SciClone Pharmaceuticals Inc Earnings Release - Before Market Open
06:17AM  SciClone posts 4Q profit Associated Press
06:00AM  SciClone Reports 2016 Financial Results And 2017 Outlook PR Newswire
Feb-28-17 06:53PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin
Feb-21-17 06:00AM  SciClone Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Financial Results On March 6, 2017 PR Newswire
Feb-01-17 06:00AM  SciClone To Present At BIO CEO & Investor Conference On February 13, 2017 PR Newswire
Jan-30-17 08:30AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : January 30, 2017 Capital Cube
08:30AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : January 30, 2017
Jan-11-17 07:25AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : January 11, 2017
Jan-06-17 04:16PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Dec-19-16 10:59AM  SciClone Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCLN) : December 19, 2016
Dec-16-16 07:38AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : December 16, 2016
Dec-13-16 03:01AM  Is Actua Corp (ACTA) a Good Stock to Buy? at Insider Monkey
Dec-02-16 09:39AM  Do Hedge Funds Love Rent-A-Center Inc (RCII)? at Insider Monkey
Nov-29-16 05:43AM  Coverage initiated on SciClone Pharma by Maxim Group
Nov-28-16 01:19PM  Is Retrophin Inc (RTRX) A Good Stock To Buy? at Insider Monkey
Nov-16-16 12:13PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : November 16, 2016
Nov-15-16 07:34AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : November 15, 2016
Nov-14-16 04:05PM  SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG Management PR Newswire +5.08%
08:24AM  Early movers: HAR, MENT, PFE, NVS, TM, JNJ, HPE, DUK, KO, CHS & more at CNBC
Nov-09-16 11:47PM  Edited Transcript of SCLN earnings conference call or presentation 9-Nov-16 9:30pm GMT +8.74%
05:12PM  SciClone posts 3Q profit
04:12PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  SciClone Reports Third Quarter 2016 Financial Results PR Newswire
07:07AM  Q3 2016 SciClone Pharmaceuticals Inc Earnings Release - After Market Close
Nov-01-16 12:18PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : November 1, 2016
Oct-25-16 12:24PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
06:00AM  SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On November 9, 2016 PR Newswire
Oct-11-16 08:16AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : October 11, 2016
Sep-29-16 10:16AM  SciClone Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCLN) : September 29, 2016
Sep-28-16 08:16AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : September 28, 2016
Sep-26-16 06:00AM  SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market PR Newswire
Sep-12-16 11:15AM  Soligenix (SNGX) and SciClone (SCLN) Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
07:00AM  Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis PR Newswire
Sep-01-16 04:05PM  SciClone To Present At Two Investor Conferences In September 2016 PR Newswire
Aug-31-16 11:49AM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : August 31, 2016
Aug-18-16 11:15PM  Sciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 million of Stocks
Aug-16-16 12:40PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : August 16, 2016
Aug-15-16 01:20PM  SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
Aug-10-16 12:41PM  Are High Composite Ratings An Automatic 'Buy' Signal? No. Here's Why
Aug-09-16 05:59PM  SciClone posts 2Q profit
04:08PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  SciClone Reports Second Quarter 2016 Financial Results PR Newswire
07:07AM  Q2 2016 SciClone Pharmaceuticals Inc Earnings Release - Time Not Supplied
Aug-03-16 02:02PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits
Jul-28-16 06:00AM  SciClone Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016 PR Newswire
Jul-20-16 12:52PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : July 20, 2016
Jul-19-16 11:37AM  Whats the Deal With These Five Stocks Trading in Red on Tuesday? at Insider Monkey -20.81%
09:21AM  SciClone Pharmaceuticals' stock tumbles after ending discussions with acquirers at MarketWatch
06:00AM  SciClone Provides Update On Strategic Review Process PR Newswire
Jul-11-16 09:58AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : July 11, 2016
Jul-06-16 02:39PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : July 6, 2016
Jun-27-16 04:29PM  SciClone Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCLN) : June 27, 2016
Jun-24-16 09:01AM  SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : June 24, 2016
Jun-15-16 12:36PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Jun-03-16 03:40PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : June 3, 2016
03:19PM  3 Biotech Stocks Headed for New Highs (SCLN, SUPN) at Investopedia
May-24-16 03:36PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : May 24, 2016
May-23-16 02:04PM  SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016
May-10-16 02:29PM  Edited Transcript of SCLN earnings conference call or presentation 10-May-16 12:30pm GMT -5.46%
07:34AM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q1 2016 SciClone Pharmaceuticals Inc Earnings Release - After Market Close
06:14AM  SciClone posts 1Q profit
06:00AM  SciClone Reports First Quarter 2016 Financial Results PR Newswire
May-03-16 09:05AM  3 Underfollowed Infectious Disease Stocks That Deserve More Attention at 24/7 Wall St.
Apr-25-16 06:00AM  SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016 PR Newswire
Apr-16-16 09:00AM  'Mad Money' Lightning Round: Con Ed, Regeneron Are My Picks at TheStreet
Apr-01-16 04:23PM  SciClone Pharmaceuticals, Inc.: Leads amongst peers with strong fundamentals
Mar-31-16 03:50PM  Here's Why SciClone Pharmaceuticals' Shares Are Soaring 14% Today at Motley Fool +13.75%
07:21AM  SunEdison's Market Cap 'Is No Longer Representative Of The Mid-Cap Market Space'
Mar-30-16 06:24PM  WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600 PR Newswire
06:00AM  SciClone To Present At Needham Healthcare Conference On April 13, 2016 PR Newswire
Mar-24-16 05:50PM  ETFs with exposure to SciClone Pharmaceuticals, Inc. : March 24, 2016
05:41PM  Soligenix Announces Recent Accomplishments and Year-End 2015 Financial Results at noodls
Mar-21-16 02:32PM  SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q4, 2015 By the Numbers
11:56AM  SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: 2015 By the Numbers
09:00AM  OxySure Therapeutics (OXYS) May Be Undervalued Compared to Others in Biotech Space Accesswire
Mar-11-16 01:29PM  SCICLONE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
05:01AM  SciClone posts 4Q profit
Mar-10-16 11:11PM  Edited Transcript of SCLN earnings conference call or presentation 10-Mar-16 9:30pm GMT
04:12PM  SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  SciClone Reports 2015 Financial Results PR Newswire
07:07AM  Q4 2015 SciClone Pharmaceuticals Inc Earnings Release - After Market Close
Mar-08-16 02:45PM  LifeSci Capital Initiates Coverage of SciClone Accesswire
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, Angiomax, and Cleviprex. The company has a strategic partnership with The Medicines Company to promote Angiomax (bivalirudin) and Cleviprex (clevidipine). SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blobel FriedhelmPresident & CEOMay 24Option Exercise3.556,29822,35898,824May 25 04:22 PM
Blobel FriedhelmPresident & CEOMay 24Sale9.366,29858,97592,526May 25 04:22 PM
Blobel FriedhelmPresident & CEOMay 23Option Exercise3.5515,16653,839107,692May 25 04:22 PM
Blobel FriedhelmPresident & CEOMay 23Sale9.3115,166141,15592,526May 25 04:22 PM
Blobel FriedhelmPresident & CEOMay 22Option Exercise3.5518,53665,803111,062May 23 04:13 PM
Blobel FriedhelmPresident & CEOMay 22Sale9.4418,536175,02692,526May 23 04:13 PM
Blobel FriedhelmPresident & CEOMay 11Option Exercise3.5518,22664,702110,752May 15 04:58 PM
Blobel FriedhelmPresident & CEOMay 11Sale10.0018,226182,31592,526May 15 04:58 PM
Blobel FriedhelmPresident & CEOMay 01Option Exercise3.5516458292,690May 03 04:45 PM
Blobel FriedhelmPresident & CEOMay 01Sale10.001641,64092,526May 03 04:45 PM
Blobel FriedhelmPresident & CEOApr 28Option Exercise3.5520071092,726Apr 28 05:49 PM
Blobel FriedhelmPresident & CEOApr 28Sale10.002002,00092,526Apr 28 05:49 PM
Blobel FriedhelmPresident & CEOApr 27Option Exercise3.552,8009,94095,326Apr 28 05:49 PM
Blobel FriedhelmPresident & CEOApr 27Sale10.012,80028,02392,526Apr 28 05:49 PM
Blobel FriedhelmPresident & CEOApr 26Option Exercise3.551,4004,97093,926Apr 28 05:49 PM
Blobel FriedhelmPresident & CEOApr 26Sale10.001,40014,00092,526Apr 28 05:49 PM
Blobel FriedhelmPresident & CEOApr 24Option Exercise3.5512,16043,168104,686Apr 24 07:55 PM
Blobel FriedhelmPresident & CEOApr 24Sale9.6412,160117,22892,526Apr 24 07:55 PM
Blobel FriedhelmPresident & CEOApr 21Option Exercise3.5516,16257,375108,688Apr 24 07:55 PM
Blobel FriedhelmPresident & CEOApr 21Sale9.4716,162153,13092,526Apr 24 07:55 PM
Blobel FriedhelmPresident & CEOApr 20Option Exercise3.5511,67841,457104,204Apr 24 07:55 PM
Blobel FriedhelmPresident & CEOApr 20Sale9.6011,678112,11192,526Apr 24 07:55 PM
Blobel FriedhelmPresident & CEOMar 22Option Exercise3.559,66234,300102,188Mar 23 04:44 PM
Blobel FriedhelmPresident & CEOMar 22Sale9.339,66290,12692,526Mar 23 04:44 PM
Blobel FriedhelmPresident & CEOMar 21Option Exercise3.5530,338107,700122,864Mar 23 04:44 PM
Blobel FriedhelmPresident & CEOMar 21Sale9.5130,338288,49692,526Mar 23 04:44 PM
Xie LanVP Finance, China CFOMar 16Sale9.601,0009,6000Mar 17 04:50 PM
Zhao HongCEO, China OperationsMar 15Option Exercise0.003,00003,000Mar 17 04:48 PM
Blobel FriedhelmPresident & CEOMar 15Option Exercise0.005,000092,526Mar 17 04:46 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceMar 15Option Exercise0.003,00003,000Mar 17 04:44 PM
Low Raymond AnthonyVP, Finance & ControllerMar 15Option Exercise0.001,250013,513Mar 17 05:29 PM
Xie LanVP Finance, China CFOMar 15Option Exercise0.001,00001,000Mar 17 04:50 PM
Zhao HongCEO, China OperationsMar 15Sale9.603,00028,8000Mar 17 04:48 PM
Blobel FriedhelmPresident & CEOMar 06Option Exercise3.553,08710,95990,613Mar 08 07:33 PM
Blobel FriedhelmPresident & CEOMar 06Sale10.303,08731,78787,526Mar 08 07:33 PM
Blobel FriedhelmPresident & CEOMar 03Option Exercise2.2913,29630,44794,309Mar 03 06:13 PM
Blobel FriedhelmPresident & CEOMar 03Sale10.0313,296133,31587,526Mar 03 06:13 PM
Blobel FriedhelmPresident & CEOMar 02Option Exercise1.084,4174,77091,943Mar 03 06:13 PM
Blobel FriedhelmPresident & CEOMar 02Sale10.014,41744,19887,526Mar 03 06:13 PM
Blobel FriedhelmPresident & CEOMar 01Option Exercise1.089,2009,93696,726Mar 03 06:13 PM
Blobel FriedhelmPresident & CEOMar 01Sale10.009,20092,01087,526Mar 03 06:13 PM
Blobel FriedhelmPresident & CEOFeb 24Option Exercise1.0882388987,607Feb 27 05:55 PM
Blobel FriedhelmPresident & CEOFeb 24Sale9.718237,99386,784Feb 27 05:55 PM
Blobel FriedhelmPresident & CEOFeb 23Option Exercise1.089,80010,58496,584Feb 23 06:16 PM
Blobel FriedhelmPresident & CEOFeb 23Sale9.769,80095,60986,784Feb 23 06:16 PM
Blobel FriedhelmPresident & CEOFeb 22Option Exercise1.089,2019,93795,985Feb 23 06:16 PM
SAXE JON SDirectorFeb 22Option Exercise2.6112,70033,147135,000Feb 23 06:27 PM
Blobel FriedhelmPresident & CEOFeb 22Sale9.869,20190,71486,784Feb 23 06:16 PM
Blobel FriedhelmPresident & CEOFeb 21Option Exercise1.0820,17621,790106,960Feb 23 06:16 PM
Blobel FriedhelmPresident & CEOFeb 21Sale9.8620,176198,95686,784Feb 23 06:16 PM
SAXE JON SDirectorFeb 16Option Exercise2.6117,30045,153122,300Feb 17 11:21 AM
Blobel FriedhelmPresident & CEOJan 25Option Exercise1.088,8689,57795,652Jan 27 05:22 PM
Blobel FriedhelmPresident & CEOJan 25Sale10.548,86893,43986,784Jan 27 05:22 PM
Blobel FriedhelmPresident & CEOJan 24Option Exercise1.0825,92527,999107,916Jan 24 07:01 PM
Blobel FriedhelmPresident & CEOJan 24Sale10.4925,925271,98686,784Jan 24 07:01 PM
Blobel FriedhelmPresident & CEOJan 23Option Exercise1.6622,80737,772104,784Jan 24 07:01 PM
Blobel FriedhelmPresident & CEOJan 23Sale10.4122,807237,50886,784Jan 24 07:01 PM
Blobel FriedhelmPresident & CEOJan 20Option Exercise1.8112,40022,44499,184Jan 24 07:01 PM
Blobel FriedhelmPresident & CEOJan 20Sale10.3812,400128,74186,784Jan 24 07:01 PM
Blobel FriedhelmPresident & CEOJan 05Option Exercise1.819,20016,65295,984Jan 05 06:52 PM
Blobel FriedhelmPresident & CEOJan 05Sale11.029,200101,38886,784Jan 05 06:52 PM
Blobel FriedhelmPresident & CEOJan 04Option Exercise1.8110018186,884Jan 05 06:52 PM
Blobel FriedhelmPresident & CEOJan 04Sale11.001001,10086,784Jan 05 06:52 PM
Blobel FriedhelmPresident & CEOJan 03Option Exercise1.8130054387,084Jan 05 06:52 PM
Blobel FriedhelmPresident & CEOJan 03Sale11.003003,30086,784Jan 05 06:52 PM
Blobel FriedhelmPresident & CEODec 22Option Exercise1.816,90112,49193,685Dec 22 06:21 PM
Blobel FriedhelmPresident & CEODec 22Sale10.406,90171,74886,784Dec 22 06:21 PM
Blobel FriedhelmPresident & CEODec 21Option Exercise1.8163,099114,209126,784Dec 22 06:21 PM
Blobel FriedhelmPresident & CEODec 21Sale10.5663,099666,61986,784Dec 22 06:21 PM
Blobel FriedhelmPresident & CEONov 22Option Exercise1.8114,14725,606100,931Nov 23 04:06 PM
Blobel FriedhelmPresident & CEONov 22Sale10.2014,147144,26586,784Nov 23 04:06 PM
Blobel FriedhelmPresident & CEONov 21Option Exercise1.8155,853101,094126,784Nov 23 04:06 PM
Blobel FriedhelmPresident & CEONov 21Sale10.2255,853570,91386,784Nov 23 04:06 PM
Blobel FriedhelmPresident & CEONov 14Option Exercise1.8124,69944,705111,483Nov 15 04:17 PM
Blobel FriedhelmPresident & CEONov 14Sale10.3324,699255,08686,784Nov 15 04:17 PM
Blobel FriedhelmPresident & CEONov 11Option Exercise1.815,3019,59592,085Nov 15 04:17 PM
Blobel FriedhelmPresident & CEONov 11Sale10.015,30153,05186,784Nov 15 04:17 PM
Blobel FriedhelmPresident & CEOOct 27Option Exercise1.8140,00072,400126,784Oct 28 04:22 PM
Blobel FriedhelmPresident & CEOOct 27Sale9.3040,000371,89286,784Oct 28 04:22 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceOct 26Option Exercise5.48134,828739,37248,995Oct 27 01:00 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceOct 26Sale10.00149,8921,498,9200Oct 27 01:00 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceOct 25Sale10.007070015,064Oct 27 01:00 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceOct 17Option Exercise5.971,0056,00016,609Oct 19 04:49 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceOct 17Sale10.001,47514,75015,134Oct 19 04:49 PM
CHANG NANCY TDirectorSep 29Option Exercise5.2040,981213,00370,000Sep 29 08:20 PM
CHANG NANCY TDirectorAug 30Sale10.337,54077,8870Aug 30 04:41 PM
CHANG NANCY TDirectorAug 29Sale10.3110,000103,1197,540Aug 30 04:41 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceAug 29Sale10.351,87219,37015,604Aug 29 05:12 PM
CHANG NANCY TDirectorAug 26Sale10.257,50076,89117,540Aug 30 04:41 PM
Blobel FriedhelmPresident & CEOAug 17Option Exercise1.08100,000108,000588,255Aug 18 07:19 PM
Blobel FriedhelmPresident & CEOAug 17Sale10.00501,8755,018,75086,380Aug 18 07:19 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceAug 16Sale10.627,80282,83717,476Aug 16 02:43 PM
Hawkins Richard JDirectorAug 12Option Exercise2.40120,000288,00054,363Aug 16 05:21 PM
King RobertSVP of Prod. Dev/Supply ChainAug 12Option Exercise4.3348,667210,93563,511Aug 16 05:28 PM
Meng ChuncaiGen. Counsel & VP ComplianceAug 12Option Exercise5.3831,083167,27523,333Aug 16 05:32 PM
Xie LanVP Finance, China CFOAug 12Option Exercise5.8632,832192,29912,187Aug 16 05:36 PM
Low Raymond AnthonyVP, Finance & ControllerAug 12Option Exercise0.001,250010,908Aug 16 05:34 PM
Zhao HongCEO, China OperationsAug 12Option Exercise0.0040,500025,000Aug 16 05:39 PM
Cheung Wilson Wai-ShunCFO & Senior VP, FinanceAug 12Option Exercise0.0040,500040,500Aug 16 02:43 PM
Blobel FriedhelmPresident & CEOAug 12Option Exercise0.0058,5000518,782Aug 16 05:41 PM